Stock SLNO SOLENO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Soleno Therapeutics, Inc.

Equities

SLNO

US8342033094

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
45.12 USD -8.35% Intraday chart for Soleno Therapeutics, Inc. +19.08% +12.10%
May. 03 Soleno Therapeutics Prices $138 Million Stock Offering MT
Apr. 30 Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to Natural History of Prader-Willi Syndrome CI

Evolution of the average Target Price on Soleno Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

93fe813705a1b5b4bc384409b.2Ik1yl6m7jieQODxW-cKYN5BHCUpWf3krs8B2gp-P2I.u8diuSrRqQ_POoi-H6lcP44UKxBPM5iQ5I4y7mkJbAiKuXewCpTcYPwpqQ~9a3b1985451f0b80dfa8fafff00999da

Analyst Recommendations on Soleno Therapeutics, Inc.

Soleno Therapeutics Insider Sold Shares Worth $784,645, According to a Recent SEC Filing MT
Piper Sandler Starts Soleno Therapeutics With Overweight Rating, $93 Price Target MT
Stifel Starts Soleno Therapeutics With Buy Rating, $63 Price Target MT
Oppenheimer Lifts Price Target on Soleno Therapeutics to $47 From $44, Maintains Outperform Rating MT
Oppenheimer Adjusts Soleno Therapeutics Price Target to $44 From $39, Maintains Outperform Rating MT
Wall St slides as rate concerns keep Treasury yields near 16-year peak RE
Cantor Fitzgerald Raises Price Target on Soleno Therapeutics to $35 From $19, Maintains Overweight Rating MT
Oppenheimer Raises Soleno Therapeutics Price Target to $14 Form $8, Maintains Outperform Rating MT
Cantor Fitzgerald Starts Soleno Therapeutics at Overweight With $19 Price Target MT
Oppenheimer Adjusts Soleno Therapeutics PT to $8 From $2 to Better Reflect Recent Reverse Stock Split, Maintains Outperform Rating MT
Oppenheimer Adjusts Soleno Therapeutics Price Target to $2 From $3, Maintains Outperform Rating MT
Oppenheimer Adjusts Soleno Therapeutics' Price Target to $3 From $5, Maintains Outperform Rating MT
History shows stocks can weather rate hike cycle RE
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
45.12 USD
Average target price
65.17 USD
Spread / Average Target
+44.43%
High Price Target
93 USD
Spread / Highest target
+106.12%
Low Price Target
51 USD
Spread / Lowest Target
+13.03%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Soleno Therapeutics, Inc.

Piper Sandler
Stifel Nicolaus
Oppenheimer
Cantor Fitzgerald

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SLNO Stock
  4. Consensus Soleno Therapeutics, Inc.